Xencor’s (XNCR) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Xencor (NASDAQ:XNCR) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $30.00 price target on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on the stock. Truist Financial restated a “buy” rating and set a $29.00 price objective (up from $27.00) on shares of Xencor in a research report on Monday, September 28th. Raymond James Financial lifted their target price on shares of Xencor from $40.00 to $46.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, September 1st. Wells Fargo & Company initiated coverage on shares of Xencor in a report on Wednesday, September 30th. They issued an “overweight” rating and a $55.00 target price on the stock. Cantor Fitzgerald increased their price target on shares of Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Xencor presently has an average rating of “Moderate Buy” and an average target price of $34.00.

Xencor Stock Down 2.6%

Shares of XNCR opened at $25.18 on Wednesday. Xencor has a 52-week low of $10.38 and a 52-week high of $30.61. The company has a market capitalization of $1.87 billion, a PE ratio of -11.60 and a beta of 0.89. The stock has a fifty day simple moving average of $25.37 and a two-hundred day simple moving average of $18.38.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.51. The business had revenue of $51.22 million for the quarter, compared to analyst estimates of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%. The company’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.41) EPS. As a group, equities analysts anticipate that Xencor will post -3.05 earnings per share for the current fiscal year.

Institutional Trading of Xencor

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in shares of Xencor by 15.5% in the third quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 572 shares during the last quarter. Allworth Financial LP increased its position in Xencor by 23.2% in the 2nd quarter. Allworth Financial LP now owns 3,436 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 646 shares during the period. WINTON GROUP Ltd increased its position in Xencor by 1.5% in the 2nd quarter. WINTON GROUP Ltd now owns 106,247 shares of the biopharmaceutical company’s stock valued at $1,711,000 after acquiring an additional 1,534 shares during the period. Integrated Wealth Concepts LLC acquired a new position in Xencor in the 2nd quarter valued at about $30,000. Finally, Diversified Trust Co raised its stake in Xencor by 16.7% during the 1st quarter. Diversified Trust Co now owns 21,528 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 3,086 shares during the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.